Logo image of CPRX

CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

USA - NASDAQ:CPRX - US14888U1016 - Common Stock

19.52 USD
+0.39 (+2.04%)
Last: 9/26/2025, 8:00:00 PM
19.41 USD
-0.11 (-0.56%)
After Hours: 9/26/2025, 8:00:00 PM
Fundamental Rating

8

Taking everything into account, CPRX scores 8 out of 10 in our fundamental rating. CPRX was compared to 540 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make CPRX a good candidate for value and growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
Each year in the past 5 years CPRX has been profitable.
CPRX had a positive operating cash flow in each of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

The Return On Assets of CPRX (21.47%) is better than 97.04% of its industry peers.
CPRX has a Return On Equity of 24.38%. This is amongst the best in the industry. CPRX outperforms 96.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 21.45%, CPRX belongs to the top of the industry, outperforming 97.59% of the companies in the same industry.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is above the industry average of 16.17%.
The last Return On Invested Capital (21.45%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROIC 21.45%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

The Profit Margin of CPRX (37.36%) is better than 97.41% of its industry peers.
CPRX's Profit Margin has been stable in the last couple of years.
CPRX's Operating Margin of 43.58% is amongst the best of the industry. CPRX outperforms 99.07% of its industry peers.
CPRX's Operating Margin has improved in the last couple of years.
CPRX has a Gross Margin of 85.78%. This is amongst the best in the industry. CPRX outperforms 88.52% of its industry peers.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
Industry RankSector Rank
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

8

2. Health

2.1 Basic Checks

CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 15.14 indicates that CPRX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 15.14, CPRX belongs to the best of the industry, outperforming 89.07% of the companies in the same industry.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.14
ROIC/WACC2.17
WACC9.9%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.71 indicates that CPRX has no problem at all paying its short term obligations.
The Current ratio of CPRX (6.71) is better than 67.41% of its industry peers.
CPRX has a Quick Ratio of 6.55. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.55, CPRX is doing good in the industry, outperforming 67.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.71
Quick Ratio 6.55
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 205.56% over the past year.
Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.54%.
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%

3.2 Future

CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.50% yearly.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.83, which indicates a very decent valuation of CPRX.
Based on the Price/Earnings ratio, CPRX is valued cheaply inside the industry as 97.04% of the companies are valued more expensively.
CPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.32.
CPRX is valuated reasonably with a Price/Forward Earnings ratio of 11.15.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.04% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.89, CPRX is valued rather cheaply.
Industry RankSector Rank
PE 11.83
Fwd PE 11.15
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaply inside the industry as 97.78% of the companies are valued more expensively.
98.15% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.7
EV/EBITDA 6.17
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.88
PEG (5Y)0.35
EPS Next 2Y15.59%
EPS Next 3Y12.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (9/26/2025, 8:00:00 PM)

After market: 19.41 -0.11 (-0.56%)

19.52

+0.39 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners85.12%
Inst Owner Change2%
Ins Owners5.59%
Ins Owner Change1.17%
Market Cap2.39B
Analysts88.57
Price Target34.68 (77.66%)
Short Float %6.93%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 11.83
Fwd PE 11.15
P/S 4.28
P/FCF 8.7
P/OCF 8.68
P/B 2.79
P/tB 3.33
EV/EBITDA 6.17
EPS(TTM)1.65
EY8.45%
EPS(NY)1.75
Fwd EY8.97%
FCF(TTM)2.24
FCFY11.5%
OCF(TTM)2.25
OCFY11.51%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.88
PEG (5Y)0.35
Profitability
Industry RankSector Rank
ROA 21.47%
ROE 24.38%
ROCE 28.34%
ROIC 21.45%
ROICexc 89.37%
ROICexgc 270.38%
OM 43.58%
PM (TTM) 37.36%
GM 85.78%
FCFM 49.19%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexcg growth 3Y8.72%
ROICexcg growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.99%
Cap/Sales 0.07%
Interest Coverage 165.59
Cash Conversion 97.81%
Profit Quality 131.65%
Current Ratio 6.71
Quick Ratio 6.55
Altman-Z 15.14
F-Score6
WACC9.9%
ROIC/WACC2.17
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
EPS Next Y13.37%
EPS Next 2Y15.59%
EPS Next 3Y12.05%
EPS Next 5Y26.5%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
Revenue Next Year16.03%
Revenue Next 2Y12.76%
Revenue Next 3Y11.61%
Revenue Next 5Y11.27%
EBIT growth 1Y183.49%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y121.55%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y121.67%
OCF growth 3Y58.35%
OCF growth 5Y47.28%